Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting

NEW YORK and MELBOURNE, Australia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS) Annual Meeting, the premier global conference for spine disease professionals. The key outcome of the trial was that a single injection of Mesoblast's proprietary allogeneic Mesenchymal Precursor Cell (MPC) product resulted in sustained improvements in pain and function at 12 months.

Investigator Dr Hyun Bae, who is Medical Director, Director of Education, Cedars-Sinai Spine Center, Cedars-Sinai Medical Center, Los Angeles; and Medical Director of the Spine Institute, Santa Monica, USA; presented summarized results on behalf of the trial investigators and stated: "There is a critical need for a non-surgical biologic approach to improve pain and function in the millions of patients suffering from chronic low back pain associated with disc degeneration. The results to date seem promising and I believe Mesoblast's stem cell therapy product could have the potential to transform the treatment of back pain."

Mesoblast's Phase 2 clinical trial enrolled 100 patients with moderate to severe low back pain persisting for more than 6 months and caused by early disc degeneration (less than 30% disc height loss, 83% below Pfirrmann Grade 5 by MRI). Patients were enrolled across 13 sites in the United States and Australia and randomized to receive direct intra-disc injection of saline (n equals 20), hyaluronic acid (HA, n equals 20), 6 million allogeneic Mesenchymal Precursor Cells (MPCs) in hyaluronic acid carrier (6M, n equals 30) or 18 million allogeneic MPCs in hyaluronic acid carrier (18M, n equals 30). Patients received the injection in the outpatient setting for a single painful degenerated lumbar level disc and are being assessed for safety and efficacy over a total of 36 months to evaluate long-term treatment effects.

The following key findings were presented to the NASS meeting:

  • Allogeneic MPCs were well tolerated
  • Both MPC doses showed improvement relative to controls for pain and functional improvement and reduced interventions
  • Radiographic evidence demonstrating decreased abnormal vertebral movement, suggesting improvement in disc structure and stability
  • MPC treated patients were three times more likely to achieve treatment success defined as clinically significant pain and function improvement without further intervention at both 6 and 12 months, when compared to controls

In line with recent discussions with the United States Food and Drug Administration (FDA), Mesoblast anticipates that it will commence the Phase 3 program by the end of this year which is expected to support product regulatory approvals.

Chronic Discogenic Low Back Pain (CDLBP)

Mesoblast's investigational product candidate MPC-06-ID is being developed to target the population of patients suffering from moderate to severe chronic low back pain due to moderately degenerated discs. The target patient population has exhausted conservative treatment options, may have failed epidural steroid injections to alleviate pain and has no treatment option other than invasive and costly surgical interventions. Over four million patients in the United States alone suffer from CDLBP. Physicians estimate a failure rate of 40% in surgically treated patients. Total costs of low back pain are estimated to be between US$100 billion and US$200 billion annually with two thirds of this amount attributed to patients' decreased wages and productivity.

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USOTC: MBLTY) is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's proprietary adult stem cell technologies include its highly purified, immunoselected Stro- 1/Stro-3 positive Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1). Mesoblast's allogeneic or 'off-the-shelf' cell-based products are targeting substantial market areas of unmet medical need, including cardiac and metabolic diseases, inflammatory/immune-mediated conditions, oncology, and orthopedic diseases. Lead products under investigation are MSC-100-IV for steroid refractory acute Graft Versus Host Disease, MPC-06-ID for chronic discogenic lower back pain and MPC-150-IM for congestive heart failure, in partnership with Teva Pharmaceutical Industries Ltd. www.mesoblast.com

CONTACT: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 (0) 3 9639 6036 E: julie.meldrum@mesoblast.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 35

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 96

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 45

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 156

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 23

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 293

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Bouygues Announces Updated Share and Voting Rights Information

Updated Category News Views 382

Monthly Disclosure of Shares and Voting Rights by Bouygues The importance of transparency in corporate governance cannot be overstated, and Bouygues, a prominent player in the construction and telecommunications sectors, prioritizes this. Presenting clear, timely, and precise updates regarding shares and voting rights reflects the company’s commitment to its...

Continue Reading
Capital Raises KT&G Stake to 8.2% Amid Global Gains

Updated Category News Views 37

Capital Research Strengthens Hold in KT&G Things have been heating up in Seoul. Capital Research and Management Company, a heavyweight in fund management, has just pushed its stake in KT&G up to 8.22%. That's a leap from the earlier 5.61% in May, and 7.21% by June. These guys manage a whopping $3.3 trillion in assets—so when they make a move, others tend to perk up and...

Continue Reading
Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 182

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Staying Ahead of the Curve: Why Trading Compliance Is Now a Strategic Advantage

Updated Category Investing Views 1309

In today’s fast-evolving financial landscape, trading compliance has become more than just a regulatory requirement—it’s a defining pillar of strategic success. As regulators tighten their grip and technology uncovers previously invisible risks, firms that embrace advanced compliance measures are not only staying protected but also gaining a competitive edge....

Continue Reading
Key Insights Into the Expanding Hydrogen Storage Sector

Updated Category News Views 180

The Rise of the Hydrogen Energy Storage Market The global hydrogen energy storage market is on the verge of significant growth, with projections indicating a remarkable CAGR of 72.1%, potentially reaching a substantial $23.7 billion by the end of 2029. This surge reflects a shift toward cleaner energy solutions, driven by advancements in technology, policy support, and a...

Continue Reading